Skip to main content
×
×
Home

Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder: Twenty-four-week placebo-controlled dose-ranging study

  • Christer Allgulander (a1), David Hackett (a2) and Eliseo Salinas (a2)
Abstract
Background

Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment.

Aims

To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD.

Method

A total of 541 out-patients, 18–86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER.

Results

All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups.

Conclusions

Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder
      Available formats
      ×
Copyright
Corresponding author
Dr C. Allgulander, Neurotec/Psychiatry, M57 Huddinge University Hospital, S-14186 Huddinge, Sweden
Footnotes
Hide All

Declaration of interest

This study was funded by Wyeth-Ayerst Research, of which D. H. and E. S. are employees. C. A. is an employee of the Karolinska Institutet, Stockholm, and was an investigator for one study centre.

Footnotes
References
Hide All
Abdelmawal, A. H., Langley, R. W., Bradshaw, C. M., et al (1999) Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. British Journal of Clinical Pharmacology, 48, 345354.
American Psychiatric Association (1994) Diagnositic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.
Bitsios, P., Szabadi, E. & Bradshaw, C. M. (1999) Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology, 143, 286292.
Fisher, P. L. & Durham, R. C. (1999) Recovery rates in generalised anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-Tacross outcome studies since 1990. Psychological Medicine, 29, 425434.
Food and Drug Administration (1989) ‘COSTART’: Coding Symbols for Thesaurus of Adverse Reactions Terms (3rd edn). Rockville, MD: FDA.
Goa, K. L. & Ward, A. (1986) Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs, 32, 114129.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Publ. (ADM). Rockville, MD: National Institute for Mental Health.
Hamilton, M. (1959) The assessment of anxiety by rating. British Journal of Medical Psychology, 32, 5055.
Judd, L. L., Kessler, R. C., Paulus, M. P., et al (1998) Comorbidity as a fundamental feature of generalised anxiety disorders: results from the National Comorbidity Survey (NCS). Acta Psychiatrica Scandinavica, 98 (suppl. 393), 611.
Kessler, R. C. & Wittchen, H. -U. (2001) GAD-associated impairment controlling for MDE in the NCS and MIDUS surveys. Psychological Medicine, in press
Melichar, J. K., Haida, A., Rhodes, C. G., et al (2001) Venlafaxine occupation at the noradrenaline reuptake site; in vivo determination in healthy volunteers. Journal of Psychopharmacology, in press.
Merikangas, K. R., Angst, J., Eaton, W., et al (1996) Comorbidity and boundaries of affective disorders with anxiety disorders and substance abuse: results of an international task force. British Journal of Psychiatry, 168 (suppl. 30), 5867.
Modigh, K., Westberg, P. & Eriksson, E. (1992) Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. Journal of Clinical Psychopharmacology, 12, 251261.
Rickels, K., Schweizer, E., Case, W. G., et al (1990) Effects of abrupt discontinuation. Archives of General Psychiatry, 47, 899907.
Rickels, K., Downing, R., Schweizer, E., et al (1993) Antidepressants for the treatment of generalised anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry, 50, 884895.
Rosenbaum, J. F., Fava, M., Hoog, S. L., et al (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry, 44, 7787.
Scharf, M. B., Kales, A., Bixler, E. O., et al (1982) Lorazepam – efficacy, side-effects, and rebound phenomena. Clinical Pharmacology and Therapeutics, 31, 175179.
Schweizer, E., Rickels, K. & Lucki, I. (1986) Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use. New England Journal of Medicine, 314, 719720.
Tyrer, R., Owen, R. T. & Cicchetti, D. V. (1984) The Brief Scale for Anxiety: a subdivision of the Comprehensive Psychopathological Rating Scale. Journal of Neurological and Neurosurgical Psychiatry, 47, 970975.
Tyrer, R., Murphy, S. & Riley, P. (1990) The Benzodiazepine Withdrawal Symptom Questionnaire. Journal of Affective Disorders, 19, 5361.
Weissmann, M. M. & Bothwell, S. (1976) Assessment of social adjustment by patient self-report. Archives of General Psychiatry, 33, 11111115.
Wittchen, H. U., Zhao, S., Kessler, R. C., et al (1994) DSM–III–R generalised anxiety disorder in the National Comorbidity Survey. Archives of General Psychiatry, 51, 355364.
Zigmond, A. S. & Snaith, R. P. (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica, 67, 361370.
Zohar, J. & Westenberg, H. G. (2000) Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica, 403, 3949.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 29 *
Loading metrics...

Abstract views

Total abstract views: 140 *
Loading metrics...

* Views captured on Cambridge Core between 3rd January 2018 - 21st April 2018. This data will be updated every 24 hours.

Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder: Twenty-four-week placebo-controlled dose-ranging study

  • Christer Allgulander (a1), David Hackett (a2) and Eliseo Salinas (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *